Table 5.
Association of SNPs situated in COMT and DRD2 with PANSS improvement rates of schizophrenia after treatment with risperidone
| Gene | Genotype (W>M) | Participants (n) | Improvement rate (%)
|
|||||
|---|---|---|---|---|---|---|---|---|
| PANSS total, mean ± SD | P-value | PANSS negative, mean ± SD | P-value | PANSS positive, mean ± SD | P-value | |||
| COMT | rs4680 G>A | <0.001* | 0.421 | 0.051 | ||||
| GG | 297 | 15.64±12.58 | 25.08±16.33 | 13.07±16.52 | ||||
| GA | 310 | 25.23±14.40** | 26.79±17.06 | 14.65±16.14 | ||||
| AA | 83 | 22.32±13.16** | 25.25±16.07 | 17.92±15.37 | ||||
| rs165599 A>G | 0.287 | <0.001* | 0.392 | |||||
| AA | 212 | 25.00±15.84 | 13.31±12.85 | 19.74±17.76 | ||||
| AG | 367 | 26.90±16.62 | 24.32±13.21** | 17.74±17.06 | ||||
| GG | 111 | 24.76±17.18 | 21.39±14.23** | 18.41±14.67 | ||||
| rs165774 G>A | 0.204 | 0.086 | 0.205 | |||||
| GG | 399 | 18.11±15.27 | 21.96±17.58 | 13.95±16.41 | ||||
| AG | 238 | 20.22±14.22 | 24.98±15.50 | 15.18±15.89 | ||||
| AA | 53 | 21.18±12.39 | 24.49±20.88 | 17.93±15.71 | ||||
| DRD1 | rs11746641 T>G | 0.060 | 0.062 | 0.169 | ||||
| TT | 354 | 17.18±15.65 | 20.41±16.56 | 12.95±16.41 | ||||
| TG | 283 | 18.55±13.58 | 23.12±17.31 | 14.87±16.07 | ||||
| GG | 53 | 22.10±12.39 | 24.79±20.33 | 16.51±15.64 | ||||
| rs11749676 G>A | 0.086 | 0.419 | 0.129 | |||||
| GG | 387 | 18.53±15.73 | 23.89±16.56 | 12.95±16.41 | ||||
| GA | 238 | 19.91±13.47 | 25.79±18.06 | 14.17±16.08 | ||||
| AA | 65 | 21.39±12.10 | 24.58±20.32 | 17.24±15.59 | ||||
| DRD2 | rs6275 C>T | <0.001* | 0.422 | 0.107 | ||||
| CC | 154 | 18.48±14.37 | 26.18±15.92 | 18.21±16.60 | ||||
| CT | 335 | 26.70±10.99** | 24.23±20.36 | 17.38±16.16 | ||||
| TT | 201 | 34.21±9.23**,*** | 26.07±18.32 | 20.43±15.98 | ||||
| rs1801028 C>G | <0.001* | <0.001* | 0.392 | |||||
| CC | 632 | 19.26±13.82 | 12.95±16.41 | 28.44±16.83 | ||||
| CG | 51 | 33.02±9.68** | 27.10±10.91** | 30.56±19.22 | ||||
| GG | 7 | 35.29±10.75** | 30.15±17.43** | 32.33±18.45 | ||||
| rs6277 C>T | <0.001* | 0.675 | 0.257 | |||||
| CC | 554 | 17.20±13.68 | 26.17±17.44 | 15.84±17.06 | ||||
| CT | 109 | 22.03±13.40** | 25.51±17.13 | 13.03±16.25 | ||||
| TT | 27 | 37.81±14.22**,*** | 28.82±16.92 | 13.95±14.60 | ||||
| DRD3 | rs6280 T>C | 0.101 | 0.606 | 0.132 | ||||
| TT | 418 | 20.99±14.04 | 26.36±17.37 | 15.31±16.95 | ||||
| TC | 212 | 22.70±13.57 | 25.37±17.39 | 12.50±16.42 | ||||
| CC | 60 | 24.54±14.78 | 24.34±14.08 | 13.88±14.96 | ||||
| DRD5 | rs6283 T>C | 0.073 | 0.543 | 0.424 | ||||
| TT | 212 | 17.98±12.98 | 26.34±13.02 | 9.67±11.08 | ||||
| TC | 348 | 19.24±14.10 | 26.85±18.65 | 11.23±14.97 | ||||
| CC | 130 | 21.48±13.75 | 24.95±16.65 | 10.78±14.00 | ||||
Notes:
*
Significant difference among three groups;
**
P<0.05, compared with the first row of genotypes for each SNP;
***
P<0.05, compared with the second row of genotypes for each SNP.
Abbreviations: COMT, catechol-O-methyltransferase; DRD1, dopamine receptor D1; DRD2, dopamine receptor D2; DRD3, dopamine receptor D3; DRD5, dopamine receptor D5; PANSS, Positive and Negative Syndrome Scale; M, mutant allele; W, wild allele.